Liv Kleppa

Liv Kleppa

Auto-generated profile, based on publicly available information

Liv Kleppa

Norwegian Coeliac Disease Research Centre Institute of Clinical Medicine University of Oslo Oslo Norway

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
M Cecilie Morland
Cecilie Morland
KAKrister A. Andersson
Krister A. Andersson
ØHØyvind P. Haugen
Øyvind P. Haugen
AHAlena Hadzic
Alena Hadzic
LKLiv Kleppa
Liv Kleppa
LBLinda Hildegard Bergersen
Linda Hildegard Bergersen
Physical exercise can improve brain function and delay neurodegeneration; however, the initial signal from muscle to brain is unknown. Here we show that the lactate receptor (HCAR1) is highly enriched in pial fibroblast-like cells that line the vessels supplying blood to the brain, and in pericyte-like cells along intracerebral microvessels. Activation of HCAR1 enhances cerebral vascular endothelial growth factor A (VEGFA) and cerebral angiogenesis. High-intensity interval exercise (5 days weekly for 7 weeks), as well as L-lactate subcutaneous injection that leads to an increase in blood lactate levels similar to exercise, increases brain VEGFA protein and capillary density in wild-type mice, but not in knockout mice lacking HCAR1. In contrast, skeletal muscle shows no vascular HCAR1 expression and no HCAR1-dependent change in vascularization induced by exercise or lactate. Thus, we demonstrate that a substance released by exercising skeletal muscle induces supportive effects in brain through an identified receptor.

1 August 2015 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
KLKnut H. Lauritzen
Knut H. Lauritzen
LKLiv Kleppa
Liv Kleppa
JAJan Magnus Aronsen
Jan Magnus Aronsen
LELars Eide
Lars Eide
HCHarald Carlsen
Harald Carlsen
LBLinda Hildegard Bergersen
Linda Hildegard Bergersen
Cardiac mitochondrial dysfunction has been implicated in heart failure of diverse etiologies. Generalized mitochondrial disease also leads to cardiomyopathy with various clinical manifestations. Impaired mitochondrial homeostasis may over time, such as in the aging heart, lead to cardiac dysfunction. Mitochondrial DNA (mtDNA), close to the electron transport chain and unprotected by histones, may be a primary pathogenetic site, but this is not known. Here, we test the hypothesis that cumulative damage of cardiomyocyte mtDNA leads to cardiomyopathy and heart failure. Transgenic mice with Tet-on inducible, cardiomyocyte-specific expression of a mutant uracil-DNA glycosylase 1 (mutUNG1) were generated. The mutUNG1 is known to remove thymine in addition to uracil from the mitochondrial genome, generating apyrimidinic sites, which obstruct mtDNA function. Following induction of mutUNG1 in cardiac myocytes by administering doxycycline, the mice developed hypertrophic cardiomyopathy, leading to congestive heart failure and premature death after ∼2 mo. The heart showed reduced mtDNA replication, severely diminished mtDNA transcription, and suppressed mitochondrial respiration with increased Pgc-1α, mitochondrial mass, and antioxidative defense enzymes, and finally failing mitochondrial fission/fusion dynamics and deteriorating myocardial contractility as the mechanism of heart failure. The approach provides a model with induced cardiac-restricted mtDNA damage for investigation of mtDNA-based heart disease.

1 December 2016 in Neurobiology of Aging
Verified
Journal Article
Closed access
KLKnut H. Lauritzen
Knut H. Lauritzen
MHMahdi Hasan-Olive
Mahdi Hasan-Olive
CRChristine E. Regnell
Christine E. Regnell
LKLiv Kleppa
Liv Kleppa
MSMorten Scheibye-Knudsen
Morten Scheibye-Knudsen
LBLinda Hildegard Bergersen
Linda Hildegard Bergersen

18 July 2012 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
LKLiv Kleppa
Liv Kleppa
PMPierre-Olivier Mari
Pierre-Olivier Mari
ELElisabeth Larsen
Elisabeth Larsen
GLGuro Flor Lien
Guro Flor Lien
CGCamille Godon
Camille Godon
AKArne Klungland
Arne Klungland
The structure specific flap endonuclease 1 (FEN1) plays an essential role in long-patch base excision repair (BER) and in DNA replication. We have generated a fluorescently tagged FEN1 expressing mouse which allows monitoring the localization and kinetics of FEN1 in response to DNA damage in living cells and tissues. The expression of FEN1, which is tagged at its C-terminal end with enhanced yellow fluorescent protein (FEN1-YFP), is under control of the endogenous Fen1 transcriptional regulatory elements. In line with its role in processing of Okazaki fragments during DNA replication, we found that FEN1-YFP expression is mainly observed in highly proliferating tissue. Moreover, the FEN1-YFP fusion protein allowed us to investigate repair kinetics in cells challenged with local and global DNA damage. In vivo multi-photon fluorescence microscopy demonstrates rapid localization of FEN1 to local laser-induced DNA damage sites in nuclei, providing evidence of a highly mobile protein that accumulates fast at DNA lesion sites with high turnover rate. Inhibition of poly (ADP-ribose) polymerase 1 (PARP1) disrupts FEN1 accumulation at sites of DNA damage, indicating that PARP1 is required for FEN1 recruitment to DNA repair intermediates in BER.

15 June 2008 in Cancer Research
Verified
Journal Article
Open access
PDF file
ELElisabeth Larsen
Elisabeth Larsen
LKLiv Kleppa
Liv Kleppa
TMTrine J. Meza
Trine J. Meza
LMLeonardo A. Meza-Zepeda
Leonardo A. Meza-Zepeda
CRChristina Rada
Christina Rada
AKArne Klungland
Arne Klungland
Flap endonuclease 1 (FEN1) processes Okazaki fragments in lagging strand DNA synthesis, and FEN1 is involved in several DNA repair pathways. The interaction of FEN1 with the proliferating cell nuclear antigen (PCNA) processivity factor is central to the function of FEN1 in both DNA replication and repair. Here we present two gene-targeted mice with mutations in FEN1. The first mutant mouse carries a single amino acid point mutation in the active site of the nuclease domain of FEN1 (Fen1E160D/E160D), and the second mutant mouse contains two amino acid substitutions in the highly conserved PCNA interaction domain of FEN1 (Fen1ΔPCNA/ΔPCNA). Fen1E160D/E160D mice develop a considerably elevated incidence of B-cell lymphomas beginning at 6 months of age, particularly in females. By 16 months of age, more than 90% of the Fen1E160D/E160D females have tumors, primarily lymphomas. By contrast, Fen1ΔPCNA/ΔPCNA mouse embryos show extensive apoptosis in the forebrain and vertebrae area and die around stage E9.5 to E11.5. [Cancer Res 2008;68(12):4571–8]

1 January 2007 in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Verified
Journal Article
Closed access
ELElisabeth Larsen
Elisabeth Larsen
TMTrine J. Meza
Trine J. Meza
LKLiv Kleppa
Liv Kleppa
AKArne Klungland
Arne Klungland